#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pustular psoriasis Ovarian cancer stage III Choroid melanoma Ischaemic stroke Follicular lymphoma stage I Malignant glioma Small intestine neuroendocrine tumour Anaemia Malignant oligodendroglioma Depression Monogenic diabetes Angiosarcoma metastatic Mantle cell lymphoma stage II Pulmonary arterial hypertension Chemical burn More trials…

    Learn about Rare Diseases

    Wolfram syndrome – Diagnostics Niemann-Pick disease – Basic Information Extranodal marginal zone B-cell lymphoma (MALT type) – Diagnostics Methylmalonic acidaemia – Life with Disease Toxic epidermal necrolysis – Basic Information Waldenstrom’s macroglobulinaemia recurrent Rhabdoid tumour – Diagnostics Congenital nephrogenic diabetes insipidus – Basic Information Thrombotic thrombocytopenic purpura – Diagnostics Factor IX deficiency – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    TETRODOTOXIN Gs-5245 BUMETANIDE Afatinib Rilpivirine Elexacaftor Cinchocaine Hydrochloride Histamine Dihydrochloride Imifoplatin Clemastine Ioversol Ataluren Kk8123 Ly4100511 Anakinra Retinol Acetate Camizestrant Valsartan Pp1815 Iron More therapies…

    Learn about Your Condition

    Bronchopulmonary dysplasia Rubella Pericarditis Cancer fatigue Anaemia Plasma cell myeloma refractory Congenital myopathy Multiple sclerosis relapse Splenic marginal zone lymphoma Aphthous ulcer Liver transplant Dermatomyositis Toxicity to various agents Hepatocellular carcinoma Epilepsy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Somogy Varmegyei Kaposi Mor Oktato Korhaz

Somogy Varmegyei Kaposi Mor Oktato Korhaz

Tallian Gyula Utca 20-32, Kaposvar, 7400, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Efficacy and Safety Evaluation of Belantamab Mafodotin Versus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Belantamab Mafodotin
    • Dexamethasone
    • Dexamethasone Ph. Eur.
    Belgium Bulgaria France Germany Greece Hungary +4
  • A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Abemaciclib
    • Leuprorelin Acetate
    • Anastrozole
    Austria Belgium Bulgaria Croatia Czechia Estonia +10
  • A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Metformin
    • Cagrilintide
    • Dapagliflozin
    Bulgaria Croatia Czechia Denmark Finland Germany +9
  • A study testing vipoglanstat for women with moderate to severe endometriosis-related pain

    Not recruiting

    2 1
    Investigated Drugs:
    • GS-248
    • VIPOGLANSTAT
    Bulgaria Czechia Hungary Italy Poland Romania
  • Study of Rocatinlimab with Topical Treatments for Adults with Moderate to Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Rocatinlimab
    Austria Belgium Bulgaria France Germany Greece +8
  • A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

    Not recruiting

    3 1
    Investigated Drugs:
    • Ziltivekimab
    Austria Belgium Bulgaria Croatia Czechia Denmark +18
  • Study of oral and injectable NNC0487-0111 (Amycretin) to find the best dose for blood sugar control in adults with type 2 diabetes taking metformin with or without SGLT2 inhibitor

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Dapagliflozin Propanediol
    • Metformin Embonate
    Bulgaria Croatia Germany Greece Hungary Poland +3
  • Study of zasocitinib (TAK-279) and apremilast compared to placebo in adults with moderate to severe plaque psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Zasocitinib
    • Apremilast
    Bulgaria Czechia France Germany Greece Hungary +3
  • Study of rocatinlimab (AMG 451) in adolescents with moderate to severe atopic dermatitis to evaluate its effectiveness and safety over 52 weeks

    Not recruiting

    3 1 1
    Belgium Croatia France Germany Greece Hungary +4
  • Comparison of SRSD107 and enoxaparin to prevent blood clots in adults undergoing knee replacement surgery

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Enoxaparin Sodium
    • SRSD107
    Bulgaria Czechia Hungary Latvia Lithuania Poland
Previous Page
1 2 3 4 5 6 … 12
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.

Numer nieprawidłowy!
Numer nieprawidłowy!